Evicenter
MarkdownMedical informationP&T meetings
Deramiocel (CAP-1002)

Duchenne muscular dystrophy

Launch
Not announced
Last updated
89 sources

Section 6 of 6

References

89 sources

  1. Aminzadeh et al. (2018) (opens in a new tab)
  2. Aminzadeh et al. (2026) (opens in a new tab)
  3. Andrews et al. (2018) (opens in a new tab)
  4. Audhya et al. (2023) (opens in a new tab)
  5. Avila-Smirnow et al. (2025) (opens in a new tab)
  6. Bever et al. (2026) (opens in a new tab)
  7. Bourke et al. (2022) (opens in a new tab)
  8. Broomfield et al. (2024) (opens in a new tab)
  9. Capricor Therapeutics (2017) (opens in a new tab)
  10. Capricor Therapeutics (2018) (opens in a new tab)
  11. Capricor Therapeutics AAN presentation (2026) (opens in a new tab)
  12. Capricor Therapeutics advisory committee update announcement (2026) (opens in a new tab)
  13. Capricor Therapeutics BLA submission announcement (2025) (opens in a new tab)
  14. Capricor Therapeutics complaint (2026) (opens in a new tab)
  15. Capricor Therapeutics FDA Advisory Committee briefing document (2026) (opens in a new tab)
  16. Capricor Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
  17. Capricor Therapeutics Form 10-K (2020) (opens in a new tab)
  18. Capricor Therapeutics Form 10-K (2026) (opens in a new tab)
  19. Capricor Therapeutics Form 10-Q (2026) (opens in a new tab)
  20. Capricor Therapeutics Form 8-K (2026) (opens in a new tab)
  21. Capricor Therapeutics fourth quarter 2018 results announcement (2019) (opens in a new tab)
  22. Capricor Therapeutics HOPE publication announcement (2019) (opens in a new tab)
  23. Capricor Therapeutics HOPE-2 protocol (2019) (opens in a new tab)
  24. Capricor Therapeutics HOPE-2 statistical analysis plan (2020) (opens in a new tab)
  25. Capricor Therapeutics HOPE-2-OLE statistical analysis plan (2024) (opens in a new tab)
  26. Capricor Therapeutics HOPE-3 MDA 2026 data announcement (2026) (opens in a new tab)
  27. Capricor Therapeutics HOPE-3 topline results announcement (2025) (opens in a new tab)
  28. Capricor Therapeutics HOPE-OLE protocol (2018) (opens in a new tab)
  29. Capricor Therapeutics HOPE-OLE statistical analysis plan (2019) (opens in a new tab)
  30. Capricor Therapeutics January 2026 regulatory update announcement (2026) (opens in a new tab)
  31. Capricor Therapeutics July 2025 regulatory update announcement (2025) (opens in a new tab)
  32. Capricor Therapeutics legal action announcement (2026) (opens in a new tab)
  33. Capricor Therapeutics MDA 2026 presentation announcement (2026) (opens in a new tab)
  34. Capricor Therapeutics MDA presentation (2026) (opens in a new tab)
  35. Capricor Therapeutics new PDUFA date announcement (2026) (opens in a new tab)
  36. Capricor Therapeutics PDUFA date extension announcement (2026) (opens in a new tab)
  37. Capricor Therapeutics PPMD 2026 presentation announcement (2026) (opens in a new tab)
  38. Capricor Therapeutics PPMD presentation (2026) (opens in a new tab)
  39. Capricor Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
  40. Capricor Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
  41. CDC (2009) (opens in a new tab)
  42. Crisafulli et al. (2020) (opens in a new tab)
  43. DMD Care Considerations Working Group care considerations part 1 (2018) (opens in a new tab)
  44. DMD Care Considerations Working Group care considerations part 2 (2018) (opens in a new tab)
  45. DMD Care Considerations Working Group care considerations part 3 (2018) (opens in a new tab)
  46. FDA (2024) (opens in a new tab)
  47. FDA (2025) (opens in a new tab)
  48. FDA briefing document (2026) (opens in a new tab)
  49. FDA presentation (2026) (opens in a new tab)
  50. Gandolla et al. (2020) (opens in a new tab)
  51. Gillman et al. (2025) (opens in a new tab)
  52. Iannaccone et al. (2026) (opens in a new tab)
  53. Innis et al. (2025) (opens in a new tab)
  54. Kariyawasam et al. (2022) (opens in a new tab)
  55. Klimchak et al. (2021) (opens in a new tab)
  56. Landfeldt et al. (2014) (opens in a new tab)
  57. Landfeldt et al. (2016) (opens in a new tab)
  58. Landfeldt et al. (2017) (opens in a new tab)
  59. Landfeldt et al. (2018) (opens in a new tab)
  60. Landfeldt et al. (2020) (opens in a new tab)
  61. Landfeldt et al. (2026) (opens in a new tab)
  62. Lempriere (2022) (opens in a new tab)
  63. Li et al. (2025) (opens in a new tab)
  64. Mayhew et al. (2013) (opens in a new tab)
  65. Mayhew et al. (2020) (opens in a new tab)
  66. McDonald et al. (2022) (opens in a new tab)
  67. McDonald et al. (2023) (opens in a new tab)
  68. McDonald et al. (2024) (opens in a new tab)
  69. McDonald et al. (2025) (opens in a new tab)
  70. McDonald et al. (2026) (opens in a new tab)
  71. MedlinePlus Genetics (opens in a new tab)
  72. Muscular Dystrophy Association (opens in a new tab)
  73. Pane et al. (2014) (opens in a new tab)
  74. Pane et al. (2018) (opens in a new tab)
  75. PharmacoEconomics–Open (2026) (opens in a new tab)
  76. Quinlivan et al. (2021) (opens in a new tab)
  77. Rogers et al. (2019) (opens in a new tab)
  78. Rogers et al. (2025) (opens in a new tab)
  79. Scavina et al. (2026) (opens in a new tab)
  80. Smith et al. (2025) (opens in a new tab)
  81. Soslow (2026) (opens in a new tab)
  82. Soslow et al. (2023) (opens in a new tab)
  83. Strober et al. (2026) (opens in a new tab)
  84. Szabo et al. (2020) (opens in a new tab)
  85. Tang and Yokota (2024) (opens in a new tab)
  86. Taylor et al. (2019) (opens in a new tab)
  87. University of California, Davis (2025) (opens in a new tab)
  88. University of California, Davis (2026) (opens in a new tab)
  89. Yip et al. (2026) (opens in a new tab)